MX2019012505A - Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso. - Google Patents

Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.

Info

Publication number
MX2019012505A
MX2019012505A MX2019012505A MX2019012505A MX2019012505A MX 2019012505 A MX2019012505 A MX 2019012505A MX 2019012505 A MX2019012505 A MX 2019012505A MX 2019012505 A MX2019012505 A MX 2019012505A MX 2019012505 A MX2019012505 A MX 2019012505A
Authority
MX
Mexico
Prior art keywords
dimethoxyquinolin
cyclopropane
oxy
phenyl
salts
Prior art date
Application number
MX2019012505A
Other languages
English (en)
Spanish (es)
Inventor
M Blazey Charles
Shah Khalid
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62683441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019012505(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MX2019012505A publication Critical patent/MX2019012505A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
MX2019012505A 2017-05-26 2018-05-26 Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso. MX2019012505A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762511714P 2017-05-26 2017-05-26
PCT/US2018/034784 WO2018218233A1 (en) 2017-05-26 2018-05-26 Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

Publications (1)

Publication Number Publication Date
MX2019012505A true MX2019012505A (es) 2019-12-19

Family

ID=62683441

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012505A MX2019012505A (es) 2017-05-26 2018-05-26 Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.

Country Status (20)

Country Link
US (3) US11279675B2 (OSRAM)
EP (1) EP3630726B1 (OSRAM)
JP (3) JP7166292B2 (OSRAM)
KR (1) KR102611445B1 (OSRAM)
CN (1) CN110621662B (OSRAM)
AU (1) AU2018272088C1 (OSRAM)
CA (1) CA3060370A1 (OSRAM)
DK (1) DK3630726T3 (OSRAM)
EA (1) EA039654B1 (OSRAM)
ES (1) ES2909390T3 (OSRAM)
HU (1) HUE058196T2 (OSRAM)
IL (1) IL270780B2 (OSRAM)
MA (1) MA48776A (OSRAM)
MX (1) MX2019012505A (OSRAM)
PL (1) PL3630726T3 (OSRAM)
PT (1) PT3630726T (OSRAM)
SG (1) SG11201909161PA (OSRAM)
UA (1) UA127760C2 (OSRAM)
WO (1) WO2018218233A1 (OSRAM)
ZA (1) ZA201906127B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2939546C (en) * 2014-02-14 2023-01-17 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
EA039654B1 (ru) * 2017-05-26 2022-02-22 Экселиксис, Инк. Кристаллические твердые формы солей n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и методы использования
CA3088200A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
TWI770624B (zh) 2018-06-15 2022-07-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途
JP7509779B2 (ja) 2018-12-13 2024-07-02 エグゼリクシス， インコーポレイテッド キナーゼ阻害剤の結晶性形態及び塩形態
CA3139148A1 (en) * 2019-06-03 2020-12-10 Exelixis, Inc. Crystalline salt forms of a kinase inhibitor
CA3245315A1 (en) 2022-03-01 2023-09-07 Synthon B.V. L(+) TARTARIC ACID CABOZANTINIB SALT AND ITS SOLID FORMS
AU2024215796A1 (en) 2023-01-31 2025-05-15 Handa Oncology, Llc Improved cabozantinib compositions and methods of use
US11814356B1 (en) 2023-03-29 2023-11-14 Apotex Inc. Salt of cabozantinib

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2651730T3 (es) 2003-09-26 2018-01-29 Exelixis, Inc. Moduladores c-Met y métodos de uso
CA2758030C (en) * 2009-01-16 2019-01-08 Exelixis, Inc. Malate salt of n-(4-{[6,7-bis(methyloxy)quin0lin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
TWI619495B (zh) 2010-07-16 2018-04-01 艾克塞里克斯公司 Ｃ-ｍｅｔ調節劑醫藥組合物
US20140057908A1 (en) 2010-09-27 2014-02-27 Exelixis, Inc. Method of Treating Cancer
EP2621481B2 (en) 2010-09-27 2022-10-19 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
CA2826751C (en) * 2011-02-10 2021-05-18 Exelixis, Inc. Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
MX2013012695A (es) 2011-05-02 2014-03-27 Exelixis Inc Metodo para el tratamiento del cancer y el dolor por cancer de hueso.
KR20140069133A (ko) 2011-09-22 2014-06-09 엑셀리시스, 인코포레이티드 골다공증의 치료방법
US9535315B2 (en) 2011-10-31 2017-01-03 Applied Materials, Inc. Method of fabricating a color filter array using a multilevel structure
JP2015505360A (ja) 2011-11-08 2015-02-19 エクセリクシス， インク． 癌治療を定量化する方法
MX2014005458A (es) 2011-11-08 2015-04-16 Exelixis Inc Inhibidor doble de met y del factor de crecimiento endotelial vascular (vegf) para el tratamiento del cáncer.
CN104649969B (zh) 2013-11-22 2019-02-12 广东东阳光药业有限公司 一种替尼类药物的盐及其制备方法
CA2939546C (en) * 2014-02-14 2023-01-17 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
EP3145913A1 (en) * 2014-05-23 2017-03-29 Mylan Laboratories Ltd. Novel polymorphs of cabozantinib (s)-malate and cabozantinib free base
CN104961680B (zh) 2014-11-07 2017-09-12 苏州晶云药物科技有限公司 N‑(4‑{[6,7‑双(甲基氧基)喹啉‑4‑基]氧基}苯基)‑n’‑(4‑氟苯基)环丙烷‑1,1‑二甲酰胺的盐酸盐及其多晶型
CN104961681B (zh) 2014-11-13 2017-06-13 苏州晶云药物科技有限公司 卡博替尼的粘酸盐及其晶型
EP3274333B1 (en) * 2015-03-25 2019-04-24 Sandoz AG Cabozantinib salts and their use as anti-cancer agents
ES2716633T3 (es) 2015-03-25 2019-06-13 Sandoz Ag Formas cristalinas de fosfato de cabozantinib e hidrocloruro de cabozantinib
US10980792B2 (en) * 2016-09-12 2021-04-20 Zhuhai Beihai Biotech Co., Ltd. Formulations of Cabozantinib
EP3551612A4 (en) * 2016-12-07 2020-08-12 MSN Laboratories Private Limited, R&D Center PROCESS FOR THE PREPARATION OF N- (4- (6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL) -N '- (4-FLUOROPHENYL) CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S) -HYDROXYBUTANYEDIOOR AND ITS POLYDROXYBUTANYMATE
EA039654B1 (ru) * 2017-05-26 2022-02-22 Экселиксис, Инк. Кристаллические твердые формы солей n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и методы использования

Also Published As

Publication number Publication date
AU2018272088A1 (en) 2019-10-17
JP7437460B2 (ja) 2024-02-22
CA3060370A1 (en) 2018-11-29
PL3630726T3 (pl) 2022-05-09
CN110621662B (zh) 2023-06-23
JP7659097B2 (ja) 2025-04-08
WO2018218233A1 (en) 2018-11-29
JP2020521732A (ja) 2020-07-27
US20220162166A1 (en) 2022-05-26
EP3630726A1 (en) 2020-04-08
EA201992803A1 (ru) 2020-04-16
MA48776A (fr) 2020-04-08
JP2022145852A (ja) 2022-10-04
UA127760C2 (uk) 2023-12-27
NZ757564A (en) 2025-05-02
HUE058196T2 (hu) 2022-07-28
EA039654B1 (ru) 2022-02-22
US12227481B2 (en) 2025-02-18
AU2018272088A8 (en) 2019-10-24
US20210261509A1 (en) 2021-08-26
AU2018272088B2 (en) 2022-06-16
US20240010621A1 (en) 2024-01-11
IL270780B1 (en) 2024-12-01
IL270780B2 (en) 2025-04-01
US11731941B2 (en) 2023-08-22
ZA201906127B (en) 2022-11-30
US11279675B2 (en) 2022-03-22
ES2909390T3 (es) 2022-05-06
DK3630726T3 (da) 2022-03-07
IL270780A (en) 2020-01-30
JP7166292B2 (ja) 2022-11-07
CN110621662A (zh) 2019-12-27
SG11201909161PA (en) 2019-10-30
AU2018272088C1 (en) 2022-09-22
PT3630726T (pt) 2022-03-02
KR102611445B1 (ko) 2023-12-06
EP3630726B1 (en) 2021-12-22
JP2024036690A (ja) 2024-03-15
KR20200010205A (ko) 2020-01-30

Similar Documents

Publication Publication Date Title
MX2019012505A (es) Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
MX2016010266A (es) Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso.
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
MX372716B (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen.
MX2018007774A (es) Compuestos heterociclicos como inmunomoduladores.
CL2018001908A1 (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen.
MX381707B (es) Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
EA201892450A1 (ru) Ароматические сульфонамидные производные
EA201890858A1 (ru) 2,4-дигидроксиникотинамиды как агонисты apj
EA201691302A1 (ru) Новые гетероциклические соединения
MX372962B (es) Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
EA201892838A1 (ru) Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
CU20170026A7 (es) Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
CL2017002354A1 (es) Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd.
EA201691674A1 (ru) 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина
EA201891586A1 (ru) Антипролиферативные соединения и их фармацевтические композиции и применения
CL2021003568A1 (es) Compuestos heteroaromáticos como inhibidores de vanina (divisional de solicitud n° 202101198)
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
DOP2021000021A (es) Compuestos heteroaromáticos como inhibidores de vanina
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
MX2019013979A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
AR104731A1 (es) Benzamidas sustituidas y métodos para utilizarlas